NCT03295565 2022-04-15
OSTRICh
The Netherlands Cancer Institute
Phase 2/3 Completed
The Netherlands Cancer Institute
University of California, San Francisco
Merrimack Pharmaceuticals
SCRI Development Innovations, LLC
Sanofi
Associació per a la Recerca Oncologica, Spain
Sanofi
Sanofi